Vitamin D and HPV
Regarding the association between vitamin D and HPV, a study of 82 patients with a positive Papanicolaou test found low serum 25(OH)D3 levels in this group, not found in the group of women with a negative Papanicolaou test (Ozgu E., et al., 2016). A work on 67 patients followed up for systemic lupus erythematosus showed that high prevalence of HPV infection in the cervix was associated with a plasma 25(OH)D level below 20 g/l, whereas those with serum 25(OH)D levels greater than or equal to 20 g/l had a lower prevalence of infection (30.7% vs 25.8%) (Garcia-Carrasco M., et al., 2015).
A study of 4343 women aged 18–59 years found that high risk HPV prevalence was correlated with a serum 25(OH)D level of 20 g/l (Gupta A., et al., 2021). Furthermore, Shim J., et al, reported in 2016 that there is an association between high prevalence of vaccine-preventable HPV and low serum 25(OH)D (Shim J., et al., 2016).
However, a recent study in 2020 did not find an association between high-risk HPV and plasma 25(OH)D concentration (Troja C., et al., 2020).
Vitamin D, known for its role in bone, also plays an anti-infective role. Indeed, it has been shown that there is a strong association between the development of active tuberculosis and low plasma 25(OH)D levels (Sato S., et al., 2012). A study by Yamshchikov AV, et al. in 2009 looked at the anti-infective effect of vitamin D in upper respiratory diseases, tuberculosis and immunodeficiency virus (Yamshchikov AV, et al., 2009). A study in the ANRS COPANA cohort demonstrated the link between low CD4 counts, increased inflammatory markers and low serum 25(OH)D levels in newly diagnosed HIV + patients (Legeai C., et al., 2013).
Regarding the relationship between vitamin D and influenza virus, a study in Norway showed that low serum vitamin D levels are closely associated with high mortality from seasonal influenza and pneumonia (Moan J., et al., 2009). A Japanese study of Japanese schoolchildren (6–15 years) between December and March demonstrated the benefit of vitamin D supplementation at 1200 IU/day on the incidence of influenza A, particularly in asthmatic children (Urashima M; et al; 2010).
Regarding the relationship between vitamin D and COVID-19 disease, one work reported the link between COVID-19 deficiency (Grant W., et al., 2020).
In fact, the anti-infective effect of vitamin D is due to its immunomodulatory role: it prevents the proliferation of T cells (Rigby W.F., et al., 1984), on the one hand, and macrophages have the capacity to produce vitamin D, on the other (Adams J.S., et al., 1983). It inhibits inflammation-inducing mediators and stimulates monocytes and macrophages.
When confronted with an infectious agent, the latter induce an over-expression of the "Toll-like receptor", the VDR (vitamin D receptor) and 1-α hydroxylase. Activated VDR leads to a decrease in pro-inflammatory cytokines (interleukin-1, interferon-γ, tumor necrosis factor-α) and an increase in anti-inflammatory cytokines (interleukin-10).
Locally produced calcitriol will stimulate macrophages leading to autophagy and synthesis of anti-microbial peptides (cathelicidin), natural anti-infectives (Talvas J., et al., 2017., Adams J.S., et al., 2009).
Vitamin D and breast cancer
In addition, due to the presence of the vitamin D receptor on the surface of breast tissue, Holick reported in 2006 that this receptor is activated by vitamin D (Holick M.F, 2006). This activation results in terminal differentiation and inhibition of cell growth (Holick M.F, 2006). Studies have suggested that vitamin D receptors are present in more than 80% of breast tumours, giving them a protective role against tumour proliferation (Colston K.W et al, 1989; Roy D et al, 2003; Pendas-Franco N et al, 2007).
A study investigating the implication of vitamin D deficiency on cancer susceptibility found an association between low serum 25(OH)D3 levels and increased prevalence of breast cancer genesis, risk of recurrence and mortality (Bilinski, K., Boyages, J., 2013). A meta-analysis of premenopausal women demonstrated the protective role of high serum vitamin D levels and the development of breast neoplasia (Estébanez, N. et al, 2018). Another study found that in patients with a serum vitamin D level below 50 nmol/l, the risk of developing breast cancer is higher in African American patients than in Hispanic patients (Wu, Y., et al., 2017). Work from randomised trials has emphasised that high vitamin D levels are associated with a reduced risk of breast cancer, with the most protective values being 150 nmol/l (Mc Donnell, S.L et al., 2018).
HPV and breast cancer
The risk factors incriminated in the genesis of breast cancer are well known: female gender, late puberty and menopause, use of oral contraceptives, smoking, etc. In addition, there is the involvement of certain oncogenic viruses, particularly HPV. Indeed, more than 40 studies conducted in 20 countries have discovered HPV gene sequences in breast neoplastic tissue (Choi J., et al., 2016; Bae J.M., Kim EH; 2016). In the USA, the prevalence of HPV in breast neoplasia was reported to be 86% in the study by Zur Hansen H. and Villiers EM (Zur Hansen H., Villiers EM., 2015). It would appear that HPV 16 and 18 are the most frequently found in breast cancer, but Chinese and Japanese studies have shown the frequent presence of HPV 33 and 58 (Choi J. et al., 2016; Bae J.M., Kim EH; 2016). The study by Lawson J.S; et al. showed the presence of high-risk HPV on benign breast tissue that developed into HPV-positive breast cancer cells 1 to 11 years later after the initial discovery of HPV (Lawson JS., et al., 2015). Furthermore, the same study reported the occurrence of HPV-induced cervical lesions before the occurrence of breast cancer in the same patient (Lawson JS., et al., 2015).
The study by Dimri G., et al. demonstrated that mammary epithelial cells are immortalised and transformed by HPV (Dimri G., et al., 2005). The work of Yasmeen A., et al. showed that non-invasive and non-metastatic breast cancer cells are transformed by HPV 16 E6 and E7 oncoproteins into invasive and metastatic cells (Yasmeen A., et al., 2007). Ngan C., et al. reports the hypotheses that HPV may indirectly influence breast cancer genesis as well as act through the "hit and run" technique in that it triggers breast cancer genesis and subsequently disappears from tumour cells not found at the time of clinical breast cancer diagnosis (Ngan C., et al., 2015). In addition, the APOBEC enzyme involved in cell cycle control appears to be influenced by HPV leading to genomic instability and ultimately to the occurrence of breast cancer (Ohba K., et al., 2014; Vieira VC, et al., 2014).